ContraVir Pharmaceuticals Inc., changes its name to Hepion Pharmaceuticals, Inc.
ContraVir Pharmaceuticals, Inc,.a biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepatitis (�NASH�) and chronic viral infection, announced that its Board of Directors has approved the change of the Company�s name and stock symbol to Hepion Pharmaceuticals, Inc. and �HEPA,� respectively.
The Company�s new NASDAQ trading symbol will be effective as of the opening of trading on July 23, 2019, as will a new CUSIP number for the Company�s common stock of 426897104.
�We derived the name �Hepion� by combining the ancient Greek word for liver, �hepar,� with �Epione,� the goddess of soothing, or healing,� commented Dr. Robert Foster, the Company�s CEO. �Changing the Company�s name to Hepion Pharmaceuticals is a reflection of the significant potential our lead candidate, CRV 431, has to treat inflammation, fibrosis, and hepatocellular carcinoma associated with liver disease, in addition to its potential as an antiviral.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins